Zoetis insider plans sale of 3,662 shares

Zoetis Inc. insider plans to sell common stock under Rule 144.

Accepted by SEC EDGAR 02/13/2026 - 04:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zoetis Inc. insider plans to sell common stock under Rule 144. A person associated with Zoetis filed a notice to sell 3,662 shares of Zoetis common stock through Merrill Lynch on or about 02/13/2026 on the NYSE, with an aggregate market value of $472,727.58.

The filing shows these shares were accumulated mainly through vesting of restricted stock unit and performance share awards, plus an employee stock option exercise between 2022 and 2025. Zoetis had 422,127,709 common shares outstanding when the notice was prepared.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Zoetis (ZTS) disclose?

The Form 144 discloses a planned sale of Zoetis common stock. An affiliated person intends to sell 3,662 shares on the NYSE, with an aggregate market value of $472,727.58, providing advance notice of a potential insider sale under SEC Rule 144.

How many Zoetis (ZTS) shares are planned for sale and what is their value?

The filing shows a planned sale of 3,662 Zoetis common shares. The aggregate market value of these shares is reported as $472,727.58, based on the market price used in the notice for the proposed Rule 144 transaction.

How were the Zoetis (ZTS) shares in the Form 144 originally acquired?

The shares came from equity compensation and option activity. They were acquired through vesting of restricted stock unit and performance share awards, and through an employee stock option exercise, all granted by Zoetis Inc. between 2022 and 2025.

What is the approximate sale date and exchange for the Zoetis (ZTS) Rule 144 shares?

The notice lists an approximate sale date of February 13, 2026. The 3,662 Zoetis common shares are planned to be sold on the New York Stock Exchange (NYSE) through Merrill Lynch as the broker handling the transaction.

How many Zoetis (ZTS) shares were outstanding when the Form 144 was prepared?

The filing reports 422,127,709 Zoetis common shares outstanding. This figure provides a baseline for understanding the scale of the planned 3,662-share sale relative to the company’s total equity at that point in time.

Does the Zoetis (ZTS) Form 144 mention material nonpublic information?

The signer represents that they do not know any undisclosed material adverse information about Zoetis. This representation is required in the notice and is intended to support compliance with securities laws governing insider sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001900620
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Zoetis Inc.
SEC File Number	001-35797
Address of Issuer	10 SYLVAN WAY PARSIPPANY NEW JERSEY 07054
Phone	973-822-7000
Name of Person for Whose Account the Securities are To Be Sold	Polzer Robert J
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3662	472727.58	422127709	02/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/12/2022	Vesting of restricted stock unit award	Zoetis Inc.			287	02/12/2022	Granted as part of issuer equity compensation plan
Common Stock	02/12/2022	Vesting of performance share award	Zoetis Inc.			1049	02/12/2022	Granted as part of issuer equity compensation plan
Common Stock	08/05/2022	Exercise of employee stock options	Zoetis Inc.			601	08/05/2022	Broker assisted cashless exercise
Common Stock	02/11/2023	Vesting of restricted stock unit award	Zoetis Inc.			186	02/11/2023	Granted as part of issuer equity compensation plan
Common Stock	02/11/2023	Vesting of performance share award	Zoetis Inc.			230	02/11/2023	Granted as part of issuer equity compensation plan
Common Stock	02/08/2024	Vesting of restricted stock unit award	Zoetis Inc.			443	02/08/2024	Granted as part of issuer equity compensation plan
Common Stock	02/10/2024	Vesting of performance share award	Zoetis Inc.			272	02/10/2024	Granted as part of issuer equity compensation plan
Common Stock	02/10/2024	Vesting of restricted stock unit award	Zoetis Inc.			181	02/10/2024	Granted as part of issuer equity compensation plan
Common Stock	02/06/2025	Vesting of restricted stock unit award	Zoetis Inc.			413	02/06/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Robert Polzer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)